Morgan Stanley’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-670,522
| Closed | -$50.5M | – | 8166 |
|
|
2022
Q2 | $50.5M | Buy |
670,522
+96,150
| +17% | +$4.27M | 0.01% | 1355 |
|
|
2022
Q1 | $15.4M | Buy |
574,372
+236,612
| +70% | +$7.95M | ﹤0.01% | 2402 |
|
|
2021
Q4 | $16.1M | Buy |
337,760
+297,357
| +736% | +$13.3M | ﹤0.01% | 2398 |
|
|
2021
Q3 | $2.69M | Sell |
40,403
-13,479
| -25% | -$960K | ﹤0.01% | 4326 |
|
|
2021
Q2 | $4.2M | Buy |
53,882
+46,909
| +673% | +$3.47M | ﹤0.01% | 3964 |
|
|
2021
Q1 | $660K | Sell |
6,973
-44,065
| -86% | -$5.24M | ﹤0.01% | 4992 |
|
|
2020
Q4 | $6.22M | Buy |
51,038
+41,571
| +439% | +$4.55M | ﹤0.01% | 3026 |
|
|
2020
Q3 | $827K | Sell |
9,467
-3,743
| -28% | -$261K | ﹤0.01% | 4344 |
|
|
2020
Q2 | $853K | Buy |
13,210
+9,922
| +302% | +$572K | ﹤0.01% | 4282 |
|
|
2020
Q1 | $147K | Sell |
3,288
-35,390
| -91% | -$1.88M | ﹤0.01% | 5015 |
|
|
2019
Q4 | $2.41M | Buy |
38,678
+30,342
| +364% | +$1.44M | ﹤0.01% | 3891 |
|
|
2019
Q3 | $314K | Buy |
8,336
+8,221
| +7,149% | +$358K | ﹤0.01% | 4910 |
|
|
2019
Q2 | $5K | Buy |
+115
| New | +$4.1K | ﹤0.01% | 6327 |
|
Morgan Stanley's TPTX Position: Q3 2022 in Review
Morgan Stanley sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 670,522 shares — an estimated $50.5M sold.
Morgan Stanley first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $50.5M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Morgan Stanley reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Morgan Stanley sold 670,522 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $50.5M.
- Morgan Stanley first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- Morgan Stanley's Turning Point Therapeutics, Inc. Common Stock position peaked at $50.5M in Q2 2022.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Morgan Stanley's 13F filing for Q3 2022, filed 14 Nov 2022.